Published Date: 26 Apr 2023
An international team of scientists has discovered the gene in the brain that causes anxiety symptoms. Importantly, it has been demonstrated that altering the gene lowers anxiety, providing an intriguing new anxiety drug target.
Read Full NewsA prostate cancer diagnosis and life during and after treatments can feel overwhelming. Alongside the shock of a diagnosis, you may be faced with multiple treatment options and asked to make a choice—surgery, radiation ...
Neuroblastoma remains one of the deadliest childhood malignancies, accounting for a disproportionate number of pediatric cancer deaths worldwide.
1.
The clinical trial of ENZAMET shows promise as a treatment for prostate cancer.
2.
Asymptomatic Brain Metastases in EGFR-Mutant NSCLC
3.
BlurryScope: A compact, AI-powered microscope for rapid, cost-effective cancer scoring
4.
New study highlights success of financial toxicity tumor board in reducing cancer treatment costs
5.
Older Men Increasingly Overtreated for Prostate Cancer, Study Suggests
1.
CENP-H in Cancer: A Key Player in Tumor Progression and a Potential Therapeutic Target
2.
How AI, Multi-Omics, and Real-World Evidence are Redefining Oncology Research and Shaping Cancer Care?
3.
Breast Cancer Secrets: AI-Powered Precision Medicine
4.
Using Node Technology to Fight Breast Cancer: A New Hope for Early Detection
5.
Cracking Oncology Drug Resistance: New Strategies to Overcome Challenges in Modern Cancer Therapy
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion
3.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
4.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part II
5.
Efficient Management of First line ALK-rearranged NSCLC - Part II
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation